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Abstract
Background: The efficacy of home fortification with iron-containing micronutrient powders varies between trials,
perhaps in part due to population differences in adherence. We aimed to assess to what extent adherence
measured by sachet count or self-reporting forms is in agreement with adherence measured by electronic device.
In addition, we explored how each method of adherence assessment (electronic device, sachet count, self-reporting
forms) is associated with haemoglobin concentration measured at the end of intervention; and to what extent
baseline factors were associated with adherence as measured by electronic device.
Methods: Three hundred thirty-eight rural Kenyan children aged 12-36 months were randomly allocated to three
treatment arms (home fortification with two different iron formulations or placebo). Home fortificants were
administered daily by parents or guardians over a 30 day-intervention period. We assessed adherence using an
electronic device that stores and provides information of the time and day of opening of the container that was
used to store the fortificants sachets in each child’s residence. In addition, we assessed adherence by self-reporting
and sachet counts. We also measured haemoglobin concentration at the end of intervention.
Results: Adherence, defined as having received at least 24 sachets (≥ 80%), during the 30-day intervention period
was attained by only 60.6% of children as assessed by the electronic device. The corresponding values were higher
when adherence was assessed by self-report (83.9%; difference: 23.3%, 95% CI: 18.8% to 27.8%) or sachet count
(86.3%; difference: 25.7%, 95% CI: 21.0% to 30.4%). Among children who received iron, each 10 openings of the
electronic cap of the sachet storage container were associated with an increase in haemoglobin concentration at
the end of intervention by 1.2 g/L (95% CI: 0.0 to 1.9 g/L). Adherence was associated with the age of the parent
but not with intervention group; with age, sex or anthropometric indices of the child; or with age or sex of the
parent or guardian.
Conclusions: The use of self -reporting and sachet count may lead to overestimates of adherence to home fortification.
Trial registration: The trial was registered with ClinicalTrials.gov (NCT02073149) on 25 February 2014.
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Background
In 2011, WHO recommended home fortification with
iron-containing micronutrient powders for children
aged 6-23 months in areas with a prevalence of
anaemia exceeding 20% [1]. The basis of this
recommendation was a meta-analysis of randomised
controlled trials showing moderate quality evidence
for an effect on anaemia and haemoglobin concentra-
tion [2]. In a recent placebo-controlled trial, however,
we failed to find effects of home fortification with
iron-containing micronutrient powders on either an-
aemia or haemoglobin concentration [3]. In addition,
in an updated meta-analysis, we showed that the
magnitude of the effect on haemoglobin concentration
varied between trials [3]. Such variability in trial re-
sults may be due in part to population differences in
adherence to home fortification. In this paper, we
conceive of adherence as the parent’s or guardian’s
act of administering home fortificants to their child
in accordance with our recommendations about
timing, dosage, frequency and method. Adherence has
been assessed in several trials by self-reporting (or
proxy reporting, in the case of guardian reporting for
children in their care) and sachet counts. Although
these assessment methods are easy to use and rela-
tively inexpensive, their reliability and validity are
controversial [4]. Both assessment methods frequently
result in overestimation of adherence because study
participants respond in a manner that they believe is
socially desirable but conceals their actual behaviour,
or participants may consciously or unconsciously fail
to return unused medication. Poor recall, particularly
over long periods, can also lead to underreporting
and underestimation of adherence [4–6].
A medication event-monitoring system (MEMS) is
a battery-operated device in a cap that fits the bottle
containing drugs or supplements. Its built-in micro-
processor records and stores date and time of all
openings. Although expensive, adherence assessment
using MEMS is superior to medication counts and
self-reporting [7, 8] and it has been considered to be
the reference standard in several trials [9, 10]. We
are not aware of studies that used MEMS to meas-
ure adherence to home fortification with micronu-
trient powders.
We aimed to assess to what extent adherence mea-
sured by sachet count or self-reporting forms is in
agreement with adherence measured by electronic de-
vices. In addition, we explored how each method of
adherence assessment (electronic device, sachet count,
self-reporting forms) is associated with haemoglobin
concentration measured at the end of intervention;
and to what extent baseline factors were associated
with adherence as measured by electronic device.
Methods
Study design
This report concerns a secondary analysis of an ex-
planatory, individually-randomised, placebo-controlled
non-inferiority trial to assess the effect of daily home
fortification on haemoglobin concentration and iron
status. We measured adherence over the 30 day-inter-
vention period using MEMS, self-reporting and sachet
counts. Details regarding study methodology are avail-
able in the study protocol [3].
Study area and participants
The study was conducted in 3 administrative areas of
Kisumu West, Kenya, in the period between January and
December 2014. A total of 433 children aged 12-
36 months were invited by field workers to the research
clinic for screening and their parents signed informed
consent forms. During the screening period, medical
staff verified their ages through birth certificates or
health cards, conducted medical examination, took an-
thropometric measurements (height and weight), and
collected venous blood (4 mL) in tubes containing
Li-heparin after 30 days of intervention for subse-
quent determination of haemoglobin concentration
(HemoCue 301, Ängelholm, Sweden).
Children who attained the following admission criteria
were randomised: aged 12–36 months; resident in the
study area and parents intending to stay in the area for
the subsequent 9 months; child had no twin; parental
consent form signed by both parents; not acutely sick or
febrile (axillary temperature ≤ 37 °C) at the time of re-
cruitment; absence of reported or suspected major sys-
temic disorder; haemoglobin concentration ≥ 70 g/L; not
severely wasted (weight-for-height z-score > − 3 SD); no
known allergy to dihydroartemisinin-piperaquine, benz-
imidazole or praziquantel; no reported history of using
anti-helminth drugs in the 1-month period before the
screening date; not at risk of malaria (e.g. because
children had received chemoprophylaxis).
To protect children against malaria and severe
anaemia during the intervention period, we administered
pre-medications to every eligible child at the end of the
screening visit. We gave a therapeutic course of
dihydroartemisinin-piperaquine (Sigma-tau, Rome, Italy;
target dose: 40 mg dihydroartemisinin/320 mg pipera-
quine), albendazole (Indoco Remedies, Mumbai, India)
and praziquantel (Cosmos, Nairobi, Kenya) [1, 11].
Interventions and follow-up
Three days after starting pre-medication, parents were
asked to bring their children again for a visit to the
research clinic, where children were randomly allocated
to receive daily home fortification for 30 days with
micronutrient powders containing: a) 3 mg iron as
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NaFeEDTA, or b) 12.5 mg iron as encapsulated ferrous
fumarate, or c) placebo (no iron). The micronutrient
powders were manufactured specifically for this trial by
DSM Nutrition Products (Johannesburg, South Africa)
and packaged in 1 g sachets. The home fortificant pow-
ders for all three groups contained the same multiple
micronutrients other than iron (Table 1) as recom-
mended by the Home Fortification Technical Advisory
Group, except folic acid, which we omitted because of
our concerns that it may be utilized by Plasmodium par-
asites and increase failure risk of antifolate drugs [12].
We do not believe that exclusion of folic acid from the
fortificants affects the generalisability of our results.
The micronutrient powders were packed in 1-g plain
white foil single-serve sachets that were identical in ap-
pearance and that did not result in apparent differences
in taste, texture or colour of uji (a gruel made from lo-
cally milled flour from either maize or sorghum grains
that is commonly given to young children in the study
area). The MEMS device comprised of a white plastic
bottle with an electronic cap and had no other marker
except the serial number, label with the child’s identifica-
tion number, date of start and end of intervention
period. Except for the trial coordinator and one field
supervisor, neither parents nor research assistants were
informed about the function of the electronic device. In-
stead they were informed that the MEMS cap is essential
for maintaining the moisture content and good hygienic
conditions of the micronutrient powders.
The research assistants gave parents a supply of 30
sachets in a plastic bottle with a MEMS electronic cap
and instructed them to add the contents of one sachet to
the child’s semi-solid, ready-prepared foods for a period of
30 days on a daily basis. Pre-school children mostly con-
sume uji. The first dose of the treatment was administered
at the research clinic. Parents were shown how to mix the
micronutrient powder with uji. Parents were trained by
the research assistants to fill out the self–reporting form
(Additional file 1) and were instructed to fill out the form
each day after the child finished consuming a meal con-
taining the micronutrient powders. They were shown how
to pack the empty sachet in an empty zip-lock plastic bag
provided to them and instructed to immediately report
any sickness or adverse reactions experienced by the child
during the intervention period. Each child was issued with
a plate, a spoon and a mug to minimise sharing of the
sachet content. A return date to the research clinic was
written on the self-reporting forms, plastic bag and
MEMS bottle, and parents were verbally informed about
this return date.
Research assistants conducted pre-announced home
visits (one visit per child per week), for a total of 3 visits
per child. These visits were denoted as ‘regular monitor-
ing’ to check if the child was still in the study area, if
parents were following protocol when administering the
fortificants, if sachets were still in the MEMS device (re-
search assistants were instructed not to open the bottle
during the home visits but to gently shake the bottle to
ascertain the contents), and to check if parents were fill-
ing out forms and storing empty sachets. The research
assistants also discussed problems or clarified proce-
dures, but they did not give parents instructions add-
itional to those given during the randomisation visit. All
observations and problems experienced by parents were
recorded in a home-visit report form and submitted to
the field supervisor at the end of each day. Sick children
were referred to the research clinic.
Parents were asked to bring their children back to the
research clinic at the end of the 30-day intervention
period, where phlebotomists collected blood and per-
formed point-of-care tests (including haemoglobin con-
centration) using the same procedures as in the screening
visit. Research assistants collected all the adherence-
measuring tools.
Adherence measuring tools
Medication events monitoring system (MEMS)
We used an electronic monitoring and time-recording de-
vice (MEMS 6 TrackCap 45 mm without LCD display;
http://www.medamigo.com/products/mems-cap) that was
given for the duration of the study to parents of participat-
ing children. This battery-operated device stores and pro-
vides detailed information of the timing of the events, e.g.
day and time intervals between openings, and percent of
prescribed doses taken [13]. Each bottle had a capacity of
Table 1 Formulation of micronutrient powders
Micronutrient Content
Vitamin A, μg RE 300
Vitamin D, μg 5
Vitamin E, mg 5
Vitamin C, mg 30
Thiamin (vitamin B1), mg 0.5
Riboflavin (vitamin B2), mg 0.5
Niacin (vitamin B3),mg 6
Vitamin B6 (pyridoxine), mg 0.5
Vitamin B12 (cobalamine), μg 0.9
Iron
EITHER iron as encapsulated ferrous fumarate, mg 12.5
OR iron as NaFeEDTA, mg 3
OR no iron (placebo) 0
Zinc, mg 5
Copper, mg 0.56
Selenium, μg 17
Iodine, μg 90
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holding 30 micronutrient sachets, and was labelled with a
child’s identification number, serial number of the elec-
tronic cap, name of the child, and a start and end date for
ease of identification and tracking. Parents were thor-
oughly instructed to open the bottle only when removing
the sachet and to close it immediately after each opening.
The research assistant demonstrated this instruction when
the first dose of powder was administered at the research
clinic. The information recorded in the MEMS cap was
downloaded at the end of the 30-day intervention period,
and stored electronically in the computer.
Sachet counts
We defined sachet count as the number of empty sa-
chets stored at the end of the intervention period. The
empty sachet was considered to be a proxy indicator that
child has consumed the content of a full sachet. Re-
search assistants instructed parents to securely keep
empty sachets in a zip-lock plastic bag marked with the
child’s name and identification number. On their return
visit to the research clinic, parents returned the empty
sachets contained in the zip-lock plastic bag, plus any
left-over full sachets in the MEMS device. The research
assistant immediately counted and recorded the empty
sachets into the Excel spread sheet. The leftover full sa-
chets remained in the MEMS bottle and were only re-
moved after the MEMS data had electronically been
transferred to PowerView software (AARDEX Group
Ltd., Sino, Switzerland). The number of full sachets was
manually recorded in the MEMS PowerView data sheet
to verify if the number of times the MEMS cap was
opened matched the sachet count.
Self-reporting form
We used a 1-page self-reporting form (Additional file 1)
that was simple and easy to fill out by a parent, even
with low level of primary education. The form had a
simple chart that allowed a parent to easily tick a box
whenever a full sachet of micronutrient powder was
administered to the child, either in the morning, mid-
morning, lunch, mid-afternoon or evening. The form
was translated into the local language (dholuo).
Definition of endpoints
Adherence to treatment was defined as the number of
days within the intervention period that the electronic
monitoring device was opened, the number of empty
sachets within the intervention period, or the number of
days within the intervention period that the child
received home fortification as reported by the mother or
guardian (designated by number of ticks on the self-
reporting form). High adherence was defined as adher-
ence ≥ 80% (24 days or more). This threshold is arbitrary
but is often used in published studies on medication
adherence [8, 13–16]. Low-adherence was defined as ad-
herence < 80% (23 days or less).
Statistical analysis
Analysis was conducted using SPSS 21 (IBM, Armonk,
NY), WHO Anthro software vs.3.2.2 (World Health
Organisation, Geneva, Switzerland), PowerView software
vs3.5.2, R-software version 3.2.0 (https://www.r-projec-
t.org) and CIA software (https://www.som.soton.ac.uk/
research/sites/cia/download/).
For children who did not complete the intervention
because parents refused supplementation after random-
isation, or due to unknown reasons, we retained 30 days
of intervention, or 30 sachets, as denominators of these
proportions. For children who were lost to follow-up
during the intervention period because they had moved
out of the study area, we initially intended to censor the
observation period at the day that the child was lost and
to use proportional weights to account for differences in
observation time between children. However, because
we could not establish the day that these children
moved, we excluded them from the analysis.
Differences in proportions of children with high adher-
ence were compared by Newcomb’s method for paired
samples. To evaluate agreement in adherence, measured
as continuous variables between various assessment
methods, we used scatter plots with corresponding
Pearson’s product-moment correlation coefficient, r. We
used t-tests and linear regression analysis to model
haemoglobin concentration at the end of 30 days of inter-
vention as a function of adherence. In these analyses, we
excluded children who received placebo.
Lastly, we used simple beta regression analysis with a
logit link to identify variables that were associated with
adherence as measured by the MEMS device. In this
analysis, we transformed the adherence outcome variable
so that fractional response values of 0 or 1 were replaced
using the formula y′ = [y + (n − 1) + 0.5]/n [17] with y
being the fractional response, and n being the sample
size. The variables examined included experimental
treatment, baseline characteristics of the child (sex, age,
being infected by P. falciparum, wasting, stunting), the
child being sick during the 30-day intervention period,
and characteristics of the parent or guardian (age,
gender, education level).
Results
Participant flow and baseline characteristics
The profile of trial participants and reasons for loss to
follow-up are presented in Fig. 1. Of 433 children invited
for screening at the research clinic, 339 were eligible.
One child was excluded after randomisation because she
was found to have a twin sister. Twenty-three children
were lost to follow-up: parents or guardians from eight
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children refused further cooperation, six children moved
residence, and nine children were lost for unknown
reasons. Fifteen participants failed to submit their self-
reporting forms, 13 participants did not return empty
sachets, one electronic cap was damaged and another was
lost. All parents who declined to continue with the study
submitted their measuring instruments and gave permis-
sion for data collected to be included in the study.
Table 2 presents baseline characteristics of study par-
ticipants. We included more boys than girls (186 versus
152), mean age (SD) was 23.6 ± 6.5 months and the dis-
tribution of children by age class was evenly distributed
between the intervention groups. At baseline, the mean
(SD) haemoglobin concentration was 105 (3.2) g/L and
62.1% (209/338) of the children were anaemic. The
prevalence of being stunted, wasted and underweight
were 30.2% (102/338), 2.9% (10/338) and 13.6% (46/338),
respectively. Mean (SD) age of primary guardians was
27.4 (6.3) years ranging from 16 to 50 years. Interviews
conducted at end of study (post intervention) showed
that about 80.2% (158/197) of the mothers administered
the sachets at home; in other cases, the child’s older sib-
lings (9.1%), extended family members (6.1%) or father
(4.1%) took up this role. Most primary guardians 71.2%
(141/197) attained upper primary education level
followed by secondary education level 20.8% (41/197),
lower primary education level 5.5% (11/197) and very
few 2.5% (5/197) attained tertiary level of education. At
the end of 30 days of intervention, the mean (SD)
haemoglobin concentration was 108.5 (12.7) g/L and the
prevalence of anaemia was about 46%.
Adherence as measured by self-reporting, sachet counts
and MEMS device
MEMS data indicated that 60.6% of children received at
least 24 sachets during the 30-day intervention period
(Table 3). That level of adherence was more frequently in-
dicated by both self-report (83.9%; difference: 23.3%, 95%
CI: 18.8% to 27.8%) and sachet count (86.3%; difference:
25.7%, 95% CI: 21.0% to 30.4%) than recorded by MEMS
(Table 3). The over-reporting by self-report and sachet
count was apparent when inspecting the scatterplots of re-
sults obtained by these methods with those obtained by
MEMS data (Fig. 2). The value for Pearson’s r expressing
the strength of the correlation between adherence by self-
report and MEMS device was 0.39 (p < 0.001), whilst the
Fig. 1 Participant flow chart
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corresponding value for the correlation between adherence
by sachet count and MEMS device was 0.38 (p < 0.001).
Adherence and haemoglobin concentration at the end of
iron intervention
Among 228 children who received home fortification with
iron, formulated either as ferrous fumarate or NaFeEDTA,
the mean (SD) haemoglobin concentration at the end of
intervention was 109.3 (12.2 g/L) g/L, with a correspond-
ing prevalence of anaemia of 44.3% (n = 101). Among these
children, we could identify an association between haemo-
globin concentration at the end of the 30-day intervention
period and adherence as assessed by MEMS (p = 0.04), but
not when assessed by self-report or sachet count (p = 0.11
and p = 0.14, respectively) (Table 4). Each 10 openings of
the electronic cap were associated with an increase in
haemoglobin concentration by 1.2 g/L (95% CI: 0.0 to 1.9).
When adherence was assessed by MEMS, we found
that children with high adherence to home fortification
with iron had higher haemoglobin concentration at the
end of the 30-day intervention period than their peers
with low adherence (111.1 g/L versus 106.6 g/L; differ-
ence: 4.6 g/L, 95% CI: 1.2 g/L to 8.0 g/L). There was no
evidence for such an association when adherence was
assessed by self-report (109.7 g/L versus 107.0 g/L; dif-
ference: 2.7 g/L, 95% CI: -1.6 g/L to 7.0 g/L) or sachet
counts (109.6 g/L versus 107.3 g/L; difference: 2.2 g/L,
95% CI: -2.6 g/L to 7.1 g/L).
Table 2 Baseline characteristics of the study population
Characteristic Placebo Iron, 3 mg as NaFeEDTA Iron, 12.5 mg as ferrous fumarate
n 112 112 114
General characteristics
Sex, male 69 (61.6%) 61 (54.5%) 56 (49.1%)
Age, months 22.8 (6.8) 23.2 (6.2) 24.9 (6.4)
Age class
12–23 months 61 (54.5%) 57 (50.9%) 44 (38.6%)
24–36 months 51 (45.5%) 55 (49.1%) 70 (61.4%)
Nutritional markers
Haemoglobin concentration, g/L 104.4 (13.2) 105.9 (13.3) 104.7 (13.3)
Anaemia
Moderate (haemoglobin concentration 70–99.99 g/L) 33 (29.5%) 34 (30.4%) 36 (31.6%)
Mild (haemoglobin concentration 100–109.99 g/L) 39 (34.8%) 31 (27.7%) 37 (32.5%)
No anaemia (haemoglobin concentration ≥ 110 g/L) 40 (35.7%) 47 (42.0%) 41 (36.0%)
Anthropometric markers
Body height, cm 80.9 (5.9) 82.1 (5.7) 82.4 (5.1)
Body weight, kg 10.6 (1.8) 10.8 (2.0) 10.9 (1.7)
Stunted (height-for-age z-score < −2 SD) 34 (30.4%) 31 (27.7%) 37 (32.5%)
Wasted (weight-for-height z-score < − 2 SD) 3 (2.7%) 5 (4.5%) 2 (1.8%)
Underweight (weight-for-age z-score < − 2 SD) 19 (17.0%) 12 (10.7%) 15 (13.2%)
Values indicate n (%), mean (SD)
Table 3 Adherence as indicated by various assessment methods during the 30-day intervention period
Adherence MEMS (n = 338) Self-reporting (n = 338) Sachet count (n = 338)
Coveragea 330 (97.6%) 317 (93.8%) 313 (92.6%)
Missingb 8 (2.4%) 21 (6.2%) 19 (5.6%)
High (≥ 80%, or ≥24 sachets consumed) 200 (60.6%) 266 (83.9%) 270 (86.3%)
Low (< 80%, or 1-23 sachets consumed) 130 (39.4%) 51 (16.1%) 43 (13.7%)
Values indicate n (%), MEMS Medication Events Monitoring System
aNumber of children who consumed at least one of the 30 sachets scheduled during the intervention period
bReasons, by intervention group: MEMS: 6 participants moved residence, 1 participant damaged the electronic device and another lost the electronic device;
Self-reporting: 6 participants moved residence; 15 others failed to submit their self-reporting forms; Sachet counts: 6 participants moved residence; 13 others failed
to return empty sachets
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Factors associated with adherence measures using
MEMS device
Adherence to home fortification was associated with the
age of the parent or guardian: for each increment in age
by 1 year, the logit of the fractional response increased
by 4% (95% CI: 1% to 6%, p = 0.002; Fig. 3). Compared
to adherence with home fortification with placebo, there
was no evident difference in adherence with home forti-
fication with iron, either as NaFeEDTA or as ferrous
fumarate (Table 5). We also found no evidence that ad-
herence was affected by baseline characteristics of the
child (sex, age, being infected by P. falciparum, wasting,
stunting), the child being sick during the 30-day inter-
vention period, or characteristics of the parent or guard-
ian (gender, education level) (Table 5).
Discussion
Compared to adherence monitoring by electronic device,
we found that self-reporting and sachet count over a
30-day intervention period was associated with over-
reporting. Among children who received iron, haemoglo-
bin concentration at the end of the 30-day intervention
period was associated with adherence as assessed by
MEMS, but there was no evidence of it being associated
with adherence as assessed by self-report or sachet count.
Each 10 openings of the electronic device were associated
with an increase in haemoglobin concentration of 1.2 g/L
(95% CI: 0.0 to 1.9). Adherence to home fortification was
associated with the age of the parent or guardian.
We assume that assessment of adherence by electronic
device is more reliable than by self-report or sachet
count. This has been reported by others [7, 8] but also
seemed to be confirmed in the present study by our
finding that adherence assessed by MEMS was associ-
ated with a haemoglobin concentration response in
children who received iron, whereas such a response
could not be shown when adherence was assessed by
self-report or sachet count. However, we cannot exclude
the possibility that there were parents who administered
missed doses on the next day in addition to the sched-
uled dose. Compared to ingestion of a single dose of
Fig. 2 Adherence measurements as assed by self-reporting and
sachet tools compared with MEMS device. Panel a Data were not
available for 17 children because 15 self-reporting forms were either
missing or not filled out and records of 2 MEMS devices missing
because 1 device was damaged and another was not returned at
end of 30 days after randomization. Panel b Data were not available
for 15 children because 13 children lost or did not return empty
sachets and 2 MEMS devices were unavailable. Not all data points in
Panel a and Panel b are visible due to over-lapping of adherence
counts. The red line indicates perfect agreement in adherence
counts between pairs of assessment methods. For each panel, data
points presented above the reference line indicate overestimation of
adherence assessed by self-report or sachet count, respectively, as
compared to adherence measured by MEMS, whereas data points
presented below the reference line indicate underestimation of
adherence measured by MEMS
Table 4 Association between adherence and haemoglobin
concentration in children who received daily home fortification
with iron as ferrous fumarate or NaFeEDTA
Adherence assessment
method
Difference in haemoglobin
concentration, g/L (95% CI)a
P-value
MEMS 1.2 (0.0 to 1.9) 0.04
Self-reporting 2.3 (−0.5 to 5.2) 0.11
Sachet count 2.7 (−0.9 to 6.3) 0.14
MEMS Medication Events Monitoring Systems
aAssociation expressed as the mean difference in haemoglobin concentration
for each increment in adherence by 10 MEMS openings, or 10 sachets
consumed as indicated by self-report or sachet count
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Fig. 3 Age of parent or guardian at baseline as a predictor of adherence to daily home fortification
Table 5 Variables associated with adherence, assessed by MEMS device
Variable Adherence Logit ratio (95% CI) p-value
Intervention group
Placebo 77.7% Reference
NaFeEDTA 79.6% 1.12 (0.84-1.49) 0.45
Ferrous fumarate 79.0% 1.08 (0.81-1.44) 0.61
Child’s sex
Male 77.8% Reference
Female 79.9% 1.13 (0.89-1.43) 0.32
Child’s age, yearsa – 0.99 (0.80-1.23) 0.92
P. falciparum, baseline
Not infected 79.9% Reference
Infected 77.2% 0.86 (0.67-1.09) 0.21
Anthropometric indices, baseline
Wasting (weight-for-height z-score change, 1 SD)a – 1.07 (0.95-1.20) 0.27
Stunting (height-for-age z-score change, 1 SD)a – 1.06 (0.97-1.15) 0.18
Underweight (weight-for-age z-score change, 1 SD)a – 1.08 (0.98-1.20) 0.12
Child was sick during intervention period
No 78.8% Reference
Yes 78.9% 1.01 (0.77-1.33) 0.95
Parental education
None 85.4% Reference
Primary 77.2% 0.58 (0.30-1.13) 0.11
Secondary 81.8% 0.77 (0.38-1.58) 0.47
Tertiary 82.7% 0.82 (0.24-2.83) 0.76
Parent’s sex
Male 64.1% Reference
Female 79.0% 2.11 (0.61-7.29) 0.24
Logit ratios indicate the change in logit relative to the reference class, or the relative change in logit associated with 1 unit increment in thea continuous variables
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non-haem iron, multiple dosing leads to a decrease in
the proportion of iron absorbed, but an increase in the
absolute amount of iron absorbed [18]. Thus, the effi-
cacy of missing a dose and doubling it on the next day is
probably in between the efficacy of regular daily dosing
and skipping a missed dose altogether. In that case, as-
sessment of adherence by sachet count may theoretically
be better than by electronic device On the other
hand, self-reporting and sachet counts have the
limitation of being prone to social desirability bias:
parents may have a tendency to overreport ‘good
behaviour’, to remove but not administer sachet con-
tents, or to underreport adherence due to inaccurate
recall or loss of sachets. Such bias has been shown in
many studies for self-reporting of medication (e.g.,
[19–21]). Thus MEMS may more actually indicate fre-
quency of intake of home fortificants powders and thus
intervention efficacy than sachet count, which is subject
to social desirability bias and may be more vulnerable
product use in unintended ways.
As reported elsewhere, we failed to find an effect of
home fortification with either 3 mg iron as NaFeEDTA or
12.5 mg iron as ferrous fumarate on haemoglobin concen-
tration, erythrocyte zinc protoporphyrin or plasma iron
markers [3]. This failure may have been due in part to the
relatively short intervention period, consumption of diets
containing high phytate and phenolic compounds and in
part to infection-associated inflammation, which was
highly prevalent in our study population. In the present
study, we found that adherence, as assessed by MEMS,
showed that only 60.6% of children consumed at least 80%
(≥ 24) sachets during the 30-day intervention period.
These data, coupled with our finding that adherence was
associated with haemoglobin concentration at the end of
the 30-day intervention period indicate that sub-optimal
adherence may also have contributed to our failure to
show efficacy.
The association between age of the parent or guardian
and adherence to home fortification should be inter-
preted with caution, because this finding was the result
of exploratory analyses. Nonetheless, this finding sup-
ports results of a trial conducted among HIV-infected
adults in Los-Angeles, where older age was associated
with higher adherence rates of anti-retroviral adherence
[22] compared to the younger patients. Thus, it is pos-
sible that in our present study the older parents more
strictly followed instructions, resulting in improved ad-
herence, compared to the younger carers. Further trials
are needed that are specifically designed to identify
and understand determinants of adherence to home
fortification of micronutrient powders. In such trials,
latent class analysis [23] may be helpful to define sub-
groups on the basis of beliefs and attitudes about
home fortification at baseline.
A strong point of our study is the use of beta
regression analysis to model adherence expressed as a
fractional response. Linear regression analysis of the un-
transformed fractional response is commonly used but
has limitations: a) the effect of explanatory variables tend
to be non-linear, particularly with responses towards the
extremes of the range [0, 1]; b) a proportion is not nor-
mally distributed (even though a normal approximation
may be reasonable if all observations are reasonably
close to 0.50); and c) the variance is not constant but
varies with the outcome, meaning it is maximised at a
population proportion of 0.50 and it shrinks when the
population proportion approaches one of the boundar-
ies. For these reasons, linear regression would be
inappropriate and was not used in our analyses. Similar
problems are likely to arise when estimating adherence
as the mean fractional response, or when comparing
groups by the mean difference in fractional response
using ANOVA or assuming t-distributions. By contrast,
fractional response data commonly follow a beta distri-
bution, which can take a wide variety of shapes, depend-
ing on the parameters describing the distribution.
Conclusions
The use of self -reporting and sachet count may lead to
overestimates of adherence to home fortification. Adher-
ence to home fortification as assessed by MEMS device
was associated with the age of the parent or guardian.
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